Prot #18-0402: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, In Subjects With Advanced Solid Tumors And Pancreatic Cancer Using Combination Therapy

Project: Research project

Project Details

StatusActive
Effective start/end date3/17/20 → 3/17/26

Funding

  • Novella Clinical, LLC ((OE) Prot #18-0402 // (OE) Prot #18-0402)
  • NGM Biopharmaceuticals, Inc. ((OE) Prot #18-0402 // (OE) Prot #18-0402)